223 related articles for article (PubMed ID: 29981282)
1. Clinical Associations with ABO Blood Group and Rhesus Blood Group Status in Patients with Breast Cancer: A Nationwide Retrospective Study of 3,944 Breast Cancer Patients in Turkey.
Akin S; Altundag K
Med Sci Monit; 2018 Jul; 24():4698-4703. PubMed ID: 29981282
[TBL] [Abstract][Full Text] [Related]
2. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer.
Yu J; Gao F; Klimberg VS; Margenthaler JA
Ann Surg Oncol; 2012 Oct; 19(10):3159-64. PubMed ID: 22878611
[TBL] [Abstract][Full Text] [Related]
3. ABO and Rh blood groups frequency in women with HER2 positive breast cancer.
Urun Y; Utkan G; Altundag K; Arslan O; Onur H; Arslan UY; Kocer M; Dogan I; Senler FC; Yalcin B; Demirkazik A; Akbulut H; Icli F
J BUON; 2012; 17(3):457-60. PubMed ID: 23033281
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
5. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
Shahi KS; Bhandari G; Singh A
J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
[TBL] [Abstract][Full Text] [Related]
6. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
[TBL] [Abstract][Full Text] [Related]
8. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
10. Significance of ABO-Rh blood groups in response and prognosis in breast cancer patients treated with radiotherapy and chemotherapy.
Cihan YB
Asian Pac J Cancer Prev; 2014; 15(9):4055-60. PubMed ID: 24935596
[TBL] [Abstract][Full Text] [Related]
11. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.
AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES
Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
15. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
Amirifard N; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
[TBL] [Abstract][Full Text] [Related]
17. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
